BioCentury
ARTICLE | Company News

Intarcia terminates Phase III diabetes trials

February 2, 2018 11:40 PM UTC

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials earlier this week evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov. The company received a complete response letter from FDA in September for an NDA seeking approval in the indication.

At the time of the CRL, Intarcia said it was in discussion with FDA regarding steps moving forward. ...